What is the recommended acute and subsequent management of a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Management of Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

All NSTEMI patients require immediate dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor), parenteral anticoagulation, and risk-stratified timing of coronary angiography—with ticagrelor as the preferred P2Y12 inhibitor for all patients regardless of planned invasive or conservative strategy. 1

Immediate Initial Management (First 10 Minutes)

Diagnostic Assessment

• Obtain a 12-lead ECG within 10 minutes of first medical contact to confirm absence of persistent ST-elevation and identify dynamic ST-segment or T-wave changes 1
• Measure high-sensitivity cardiac troponin at 0 hours and 1 hour using validated algorithms for rapid rule-in/rule-out; if inconclusive, repeat at 3-6 hours 1
• Admit to a monitored unit with continuous rhythm monitoring for at least 24 hours to detect life-threatening arrhythmias 1

Immediate Pharmacotherapy

• Aspirin: 162-325 mg loading dose (chewable, non-enteric coated) immediately, followed by 75-100 mg daily indefinitely 1
• Oxygen: Only if arterial saturation <90%; routine oxygen is not recommended 1
• Nitroglycerin: Sublingual or IV for ongoing chest pain, unless systolic BP <90 mmHg, severe bradycardia/tachycardia, right ventricular infarction, or phosphodiesterase inhibitor use within 24-48 hours 1
• Morphine: IV for pain unrelieved by nitroglycerin, but use cautiously as it may delay P2Y12 inhibitor absorption 1

Antiplatelet Therapy Strategy

P2Y12 Inhibitor Selection (Critical Decision Point)

Ticagrelor is the preferred agent for all NSTEMI patients because it reduces mortality compared to clopidogrel and can be used regardless of whether coronary anatomy is known 1:

• Ticagrelor: 180 mg loading dose, then 90 mg twice daily 1

Prasugrel is reserved for patients proceeding to PCI and should only be given after coronary anatomy is defined at angiography 1:

• Prasugrel: 60 mg loading dose, then 10 mg daily (reduce to 5 mg daily if age ≥75 years or weight <60 kg) 1
• Contraindicated in patients with prior stroke or TIA 1

Clopidogrel is third-line, used only when ticagrelor or prasugrel are unavailable, contraindicated, or not tolerated 1:

• Clopidogrel: 300-600 mg loading dose, then 75 mg daily 1

Critical Timing Issue

Do not routinely pre-treat with a P2Y12 inhibitor when coronary anatomy is unknown and an early invasive strategy is planned 1. This preserves the option to use prasugrel (which has superior outcomes in PCI) and reduces bleeding risk. However, ticagrelor may be given early because it can be used regardless of anatomy 1.

Duration

Continue the P2Y12 inhibitor for at least 12 months after NSTEMI, regardless of whether a stent was placed 1

Anticoagulation Strategy

Universal Requirement

All NSTEMI patients require immediate parenteral anticoagulation in addition to dual antiplatelet therapy 1

Agent Selection Based on Renal Function and Strategy

Clinical Scenario	Preferred Agent	Dosing	Duration
Normal-to-mild renal impairment (CrCl >30 mL/min)	Enoxaparin	1 mg/kg SC q12h	Through hospitalization, up to 8 days [1]
Severe renal impairment (CrCl ≤30 mL/min)	Unfractionated heparin (UFH)	60 U/kg bolus (max 4,000 U), then 12 U/kg/h infusion (max 1,000 U/h); target aPTT 1.5-2.0 × control	≥48 hours or until PCI [1]
Conservative strategy	Fondaparinux	2.5 mg SC daily	Through hospitalization, up to 8 days [1]
Early invasive strategy	UFH or Enoxaparin	As above	As above [1]

Critical Anticoagulation Pitfalls

• Never switch between anticoagulants—this increases bleeding risk 2
• Fondaparinux cannot be used alone during PCI—must add UFH bolus to prevent catheter thrombosis 1

Risk Stratification and Timing of Invasive Strategy

Immediate Invasive Strategy (<2 Hours)

Indicated for very high-risk patients with any of the following 1:

• Hemodynamic instability or cardiogenic shock
• Refractory or recurrent chest pain despite optimal medical therapy
• Life-threatening arrhythmias (sustained ventricular tachycardia, ventricular fibrillation) or cardiac arrest
• Mechanical complications of MI (acute mitral regurgitation, ventricular septal defect)
• Acute heart failure with refractory angina or ST-segment deviation

Early Invasive Strategy (<24 Hours)

Indicated for high-risk patients with any of the following 1:

• Elevated cardiac troponin with high-risk features
• Dynamic ST-segment or T-wave changes (symptomatic or silent)
• GRACE score >140
• Diabetes mellitus
• Recurrent symptoms despite medical therapy

Standard Invasive Strategy (<72 Hours)

Indicated for intermediate-risk patients with any of the following 1:

• Renal insufficiency (eGFR <60 mL/min/1.73 m²)
• LVEF <40% or congestive heart failure
• Early post-infarction angina
• Recent PCI or prior CABG
• GRACE score 109-140

Conservative Strategy

Appropriate for 1:

• Low GRACE score without ongoing ischemia
• Patients with extensive comorbidities where revascularization risks outweigh benefits
• Patients who will not consent to revascularization

Glycoprotein IIb/IIIa Inhibitor Use

Do not use GP IIb/IIIa inhibitors routinely or upstream 1. Reserve for bail-out situations during PCI such as no-reflow or thrombotic complications 1. The 2021 ESC guidelines represent a major shift away from routine GP IIb/IIIa use due to increased bleeding without mortality benefit 1.

Post-Angiography Management

If PCI Is Performed

• Continue aspirin indefinitely 1
• Administer P2Y12 inhibitor loading dose if not given before angiography 1
• Discontinue parenteral anticoagulation immediately after uncomplicated PCI 1

If CABG Is Planned

• Continue aspirin through surgery 1
• Stop clopidogrel 5-7 days before elective CABG 1
• Stop ticagrelor 5 days before CABG 1
• Stop prasugrel at least 7 days before CABG 1
• Switch from enoxaparin to UFH 12-24 hours before CABG 1
• Switch from fondaparinux to UFH 24 hours before CABG 1
• Switch from bivalirudin to UFH 3 hours before CABG 1

If Conservative Medical Management Is Chosen

• Continue aspirin indefinitely 1
• Administer P2Y12 inhibitor loading dose if not given before angiography 1
• Continue UFH for at least 48 hours or enoxaparin/fondaparinux for duration of hospitalization 1
• Perform stress testing 24-48 hours after clinical stability to assess for inducible ischemia 1, 2

Anti-Ischemic Therapy

Beta-Blockers

• Initiate early with IV dose if ongoing chest pain, followed by oral therapy, unless contraindicated (acute heart failure, bradycardia, hypotension, severe reactive airway disease) 1
• Especially important in patients with prior MI, LV dysfunction, or ongoing ischemia 1

Nitrates

• Continue sublingual or IV nitroglycerin for ongoing symptoms 1
• IV nitrates are indicated for uncontrolled hypertension or signs of heart failure 1

Calcium Channel Blockers

• Use non-dihydropyridine agents (verapamil or diltiazem) only if beta-blockers are contraindicated and there is ongoing ischemia, but avoid in severe LV dysfunction 1
• Never use immediate-release dihydropyridines (nifedipine) without adequate beta-blockade—associated with increased mortality 1, 2

Long-Term Secondary Prevention

Mandatory Interventions

• High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg) started as early as possible and continued indefinitely 1
• ACE inhibitors for all patients with heart failure, LV dysfunction (LVEF <40%), hypertension, or diabetes 1, 2
• ARBs for patients intolerant to ACE inhibitors 1
• Beta-blockers continued long-term, especially if LV dysfunction or prior MI 1
• Measure LVEF in all patients; if ≤0.40, consider diagnostic angiography 1, 2

Lifestyle and Risk Factor Modification

• Smoking cessation with counseling and pharmacotherapy 1
• Blood pressure control (goal <130/80 mmHg) 1
• Diabetes management (HbA1c <7%) 1
• Regular physical activity and cardiac rehabilitation 1

Special Populations and Critical Pitfalls

Patients with Active Gastrointestinal Bleeding

• Continue aspirin 81 mg daily unless bleeding is immediately life-threatening—cardiovascular mortality benefit outweighs bleeding risk 2
• Defer dual antiplatelet therapy until bleeding source is controlled 2
• Do not use GP IIb/IIIa inhibitors 2
• Initiate high-dose IV PPI (80 mg bolus, then 8 mg/h × 72 hours), then oral PPI indefinitely 2
• Heparin may be justified only if ongoing refractory ischemia persists despite optimal anti-ischemic therapy 2

Patients Requiring Oral Anticoagulation

• After PCI with stenting, use triple antithrombotic therapy for the shortest duration possible (typically 1 week to 1 month), then transition to dual therapy (oral anticoagulant + single antiplatelet agent, preferably clopidogrel) 1
• Target INR 2.0-2.5 (lower than standard 2.5-3.5) when combining warfarin with dual antiplatelet therapy 2
• Do not use ticagrelor or prasugrel in combination with oral anticoagulation—use clopidogrel 1

Absolute Contraindications

• Fibrinolytic therapy is absolutely contraindicated in NSTEMI—it provides no benefit and increases harm 1
• Avoid NSAIDs (except aspirin) during hospitalization—associated with increased mortality, reinfarction, hypertension, heart failure, and myocardial rupture 1, 2
• Do not administer IV ACE inhibitors within the first 24 hours—increased risk of hypotension 1, 2

Key Algorithmic Approach

1. Immediate (0-10 min): ECG, aspirin 162-325 mg, high-sensitivity troponin
2. Early (10-60 min): Ticagrelor 180 mg (unless anatomy unknown and PCI planned within 24h), parenteral anticoagulation based on renal function, anti-ischemic therapy
3. Risk stratification: GRACE score, troponin trend, ECG changes, hemodynamic status
4. Invasive timing: Very high-risk <2h, high-risk <24h, intermediate-risk <72h
5. Post-procedure: Continue aspirin indefinitely, P2Y12 inhibitor × 12 months, high-intensity statin, ACE inhibitor if indicated, beta-blocker

This evidence-based approach prioritizes the most recent 2021 ESC guidelines 1 and 2016 ESC guidelines 1, which represent the highest quality and most contemporary evidence, while incorporating key recommendations from ACC/AHA guidelines 1 where they provide complementary guidance.